Novozymes will acquire US based Microbiome Labs in a $125 million deal, it said on Friday, its second takeover this year of a company specialising in probiotics and gut health.
“Over the span of just a few years, the team at Microbiome Labs has built a solid market position and become a key opinion leader on the microbiome in the consumer health industry,” Chief Executive Ester Baiget said in a statement.
The deal, financed through cash and bank facilities, is expected to close in the first half of January next year, and is not subject to antitrust filings.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
